Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder

• Published in: Journal of psychopharmacology (Oxford) 2024-06, Vol.38 (6), p.526-531
• Main Authors: Rafizadeh, Reza, Sooch, Anmol, Risi, Alessia, Bihelek, Nicoline, Kanegawa, Kyler, Barr, Alasdair M, White, Randall F, Schütz, Christian G, Bousman, Chad A
• Format: Article
• Language: English
• Subjects: Adult; Antipsychotic Agents - administration & dosage; C-reactive protein; C-Reactive Protein - metabolism; Clozapine; Clozapine - administration & dosage; Clozapine - pharmacokinetics; Cohort Studies; Dose-Response Relationship, Drug; Female; Fluvoxamine; Humans; Male; Mental disorders; Metabolism; Middle Aged; Obesity; Original Papers; Patients; Population studies; Psychosis; Psychotic Disorders - drug therapy; Psychotic Disorders - metabolism; Ratios; Renal function; Retrospective Studies; Schizophrenia; Schizophrenia, Treatment-Resistant - drug therapy; Sex Factors; Young Adult
• ISSN: 0269-8811; 1461-7285; 1461-7285
• DOI: 10.1177/02698811241241394

Background: There is high inter-individual variability in clozapine metabolism due to genetic and non-genetic differences. Patient-specific factors such as smoking, inflammation indicated by elevated C-reactive protein (CRP), and certain concurrent medications have a significant influence on clozapine metabolism. Aim: To assess which patient-specific factors best explain variability in clozapine metabolism estimated by clozapine concentration to dose (C/D) ratios. Methods: A retrospective cohort analysis using electronic medical data was conducted on 172 inpatients at the BC Psychosis Program. Patients with normal renal and liver function were included if they were on clozapine and had at least one steady-state plasma concentration. The degree of influence of each factor on the variability of clozapine metabolism in the entire cohort and subgroups stratified by fluvoxamine use was evaluated using multiple linear regression analysis of C/D ratios. Results: Model fit testing showed that the entire cohort model accounts for 52.7% of C/D ratio variability, while the no fluvoxamine and fluvoxamine models accounted for 40.8% and 43.8%. In the entire cohort (n = 172), fluvoxamine use explained the highest variance, and C/D ratios were higher by 30.6% on average. The second strongest predictor was elevated CRP > 10 mg/L, and C/D ratios were higher by 22.9% on average. Subsequently, obesity, nonsmoker status, and female sex explained a significant but modest proportion of variance. Among participants on fluvoxamine (n = 58), only fluvoxamine dose was associated with an increase, and for every 25 mg increase in dose, C/D ratios increased by 5% on average. Conclusion: In a clinical population, this study replicated the relationship between reduced rate of clozapine metabolism and the use of fluvoxamine, elevated CRP, obesity, nonsmoking status, and female sex; and the magnitude of the effects were large enough to be clinically relevant.